Drugs / BCB-276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07680439 | Jul 2026 → Oct 2028 expected | diffuse intrinsic pontine glioma | BrainChild Bio, Inc | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-15 | BrainChild Bio, Inc | Regulatory FDA grants Regenerative Medicine Advanced Therapy designation forBrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors brainchildbio.com ↗ |
| 2025-04-22 | BrainChild Bio, Inc | Regulatory FDA grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors brainchildbio.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCB-276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07680439 ↗ |
| Modality | Cell therapy | “BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy” NCT07680439 ↗ |
| Route | Other | “BCB-276 is administered intraventricularly (into the fluid around the brain)” NCT07680439 ↗ |